{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T17:55:05Z","timestamp":1792000505156,"version":"4.4.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T00:00:00Z","timestamp":1726272000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["CDT-142654"],"award-info":[{"award-number":["CDT-142654"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100023331","name":"LEO Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>The incidence of arterial thromboembolism (ATE) among ambulatory cancer patients varies by primary tumour site. However, it is unclear whether this alters the benefit-to-harm profile of prophylactic anticoagulation for ATE prevention. Therefore, we systematically evaluated the efficacy and safety of anticoagulants for ATE prevention among ambulatory cancer patients according to the primary tumour site.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>We conducted a systematic review using Medline, Embase, SCOPUS, and CENTRAL, and included randomized trials comparing prophylactic anticoagulation to no anticoagulation among ambulatory cancer patients who initiated tumour-directed systemic therapy. The incidence of symptomatic ATE (acute ischaemic stroke, acute myocardial infarction, or peripheral artery occlusion) and major bleeding, as well as risk differences (RDs) attributable to anticoagulation, were meta-analysed by primary tumour site using random-effects modelling. We included 10 randomized controlled trials with 9875 patients with follow-up ranging from 3.3 to 68 (median 6.6) months. While prophylactic anticoagulation did not reduce ATE risks overall (RD \u22120.49%; 95% CI \u22120.49% to 0.01%; I2\u00a0=\u00a00%), it conferred a protective effect among pancreatic cancer patients (RD \u22123.2%; 95%CI \u22125.7% to \u22120.8%; I2\u00a0=\u00a00%) without a detectable increase in major bleeding (RD \u22121.4%; 95% CI \u22124.6% to 1.8%; I2\u00a0=\u00a00%). Prophylactic anticoagulation was not associated with ATE risk reduction in other tumour sites.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Based on available evidence, prophylactic anticoagulation did not reduce ATE risk among ambulatory cancer patients overall. However, we observed a lower incidence of ATE among pancreatic cancer patients randomized to receive anticoagulation. Prophylactic anticoagulant use to reduce ATEs in pancreatic cancer should be evaluated in future research.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ehjcvp\/pvae068","type":"journal-article","created":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T08:37:21Z","timestamp":1726303041000},"page":"665-675","source":"Crossref","is-referenced-by-count":7,"title":["Anticoagulation for the prevention of arterial thromboembolism in cancer patients by primary tumour site: a systematic review and meta-analysis of randomized trials"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7429-4724","authenticated-orcid":false,"given":"Yan","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa , Ottawa, K1H 8M2 ,","place":["Canada"]},{"name":"School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa , Ottawa , K1G 5Z3,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Mallity","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa , Ottawa, K1H 8M2 ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin","family":"Collins","sequence":"additional","affiliation":[{"name":"School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa , Ottawa , K1G 5Z3,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah M","family":"Siegal","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa , Ottawa, K1H 8M2 ,","place":["Canada"]},{"name":"School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa , Ottawa , K1G 5Z3,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Fei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa , Ottawa, K1H 8M2 ,","place":["Canada"]},{"name":"School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa , Ottawa , K1G 5Z3,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8296-2972","authenticated-orcid":false,"given":"Marc","family":"Carrier","sequence":"additional","affiliation":[{"name":"Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa , Ottawa, K1H 8M2 ,","place":["Canada"]},{"name":"School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa , Ottawa , K1G 5Z3,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,9,13]]},"reference":[{"key":"2025011107300095800_bib1","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"Khorana","year":"2007","journal-title":"J Thromb Haemost"},{"key":"2025011107300095800_bib2","doi-asserted-by":"publisher","first-page":"e1001275","DOI":"10.1371\/journal.pmed.1001275","article-title":"Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis","volume":"9","author":"Horsted","year":"2012","journal-title":"PLoS Med"},{"key":"2025011107300095800_bib3","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1016\/j.jacc.2019.01.017","article-title":"Anticoagulation strategies in patients with cancer: JACC review topic of the week","volume":"73","author":"Mosarla","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2025011107300095800_bib4","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jaccao.2023.04.003","article-title":"Anticoagulation for the prevention of arterial thrombosis in ambulatory cancer patients: systematic review and meta-analysis","volume":"5","author":"Xu","year":"2023","journal-title":"JACC CardioOncology"},{"key":"2025011107300095800_bib5","doi-asserted-by":"publisher","first-page":"926","DOI":"10.1016\/j.jacc.2017.06.047","article-title":"Risk of arterial thromboembolism in patients with cancer","volume":"70","author":"Navi","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2025011107300095800_bib6","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1182\/blood.2020005125","article-title":"Thrombosis in patients with myeloma treated in the myeloma IX and myeloma XI phase 3 randomized controlled trials","volume":"136","author":"Bradbury","year":"2020","journal-title":"Blood"},{"key":"2025011107300095800_bib7","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1111\/jth.13387","article-title":"A meta-analysis of intracranial hemorrhage in patients with brain tumors receiving therapeutic anticoagulation","volume":"14","author":"Zwicker","year":"2016","journal-title":"J Thromb Haemost"},{"key":"2025011107300095800_bib8","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"2025011107300095800_bib9","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1177\/1076029611433769","article-title":"Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III\/IV lung cancer","volume":"18","author":"Haas","year":"2012","journal-title":"Clin App Thromb Haemost"},{"key":"2025011107300095800_bib10","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/S0140-6736(09)60205-1","article-title":"Warfarin thromboprophylaxis in cancer patients with central venous catheters (WARP): an open-label randomised trial","volume":"373","author":"Young","year":"2009","journal-title":"Lancet"},{"key":"2025011107300095800_bib11","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00280-013-2169-y","article-title":"Prophylaxis of catheter-related deep vein thrombosis in cancer patients with low-dose warfarin, low molecular weight heparin, or control: a randomized, controlled, phase III study","volume":"72","author":"Lavau-Denes","year":"2013","journal-title":"Cancer Chemother Pharmacol"},{"key":"2025011107300095800_bib12","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1001\/jamaoncol.2023.3634","article-title":"Risk-directed ambulatory thromboprophylaxis in lung and gastrointestinal cancers: the TARGET-TP randomized clinical trial","volume":"9","author":"Alexander","year":"2023","journal-title":"JAMA Oncol"},{"key":"2025011107300095800_bib13","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1200\/JCO.2015.64.0268","article-title":"Randomized Phase III trial of standard therapy plus low molecular weight heparin in patients with lung cancer: FRAGMATIC trial","volume":"34","author":"Macbeth","year":"2016","journal-title":"J Clin Oncol"},{"key":"2025011107300095800_bib14","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1093\/annonc\/mdx716","article-title":"Randomized phase III trial of low-molecular-weight heparin enoxaparin in addition to standard treatment in small-cell lung cancer: the RASTEN trial","volume":"29","author":"Ek","year":"2018","journal-title":"Ann Oncol"},{"key":"2025011107300095800_bib15","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1016\/S0140-6736(94)90008-6","article-title":"Double-blind randomised trial of a very-low-dose warfarin for prevention of thromboembolism in stage IV breast cancer","volume":"343","author":"Levine","year":"1994","journal-title":"Lancet"},{"key":"2025011107300095800_bib16","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1056\/NEJMoa1108898","article-title":"Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer","volume":"366","author":"Agnelli","year":"2012","journal-title":"New Engl J Med"},{"key":"2025011107300095800_bib17","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"New Engl J Med"},{"key":"2025011107300095800_bib18","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.ejca.2011.10.017","article-title":"Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer","volume":"48","author":"Maraveyas","year":"2012","journal-title":"Eur J Cancer"},{"key":"2025011107300095800_bib19","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1200\/JCO.2010.31.9293","article-title":"Randomized trial of the effect of the low molecular weight heparin nadroparin on survival in patients with cancer","volume":"29","author":"Van Doormaal","year":"2011","journal-title":"J Clin Oncol"},{"key":"2025011107300095800_bib20","doi-asserted-by":"publisher","first-page":"1801220","DOI":"10.1183\/13993003.01220-2018","article-title":"Anti-tumour effect of low molecular weight heparin in localised lung cancer: a phase III clinical trial","volume":"52","author":"Meyer","year":"2018","journal-title":"Eur Resp J"},{"key":"2025011107300095800_bib21","doi-asserted-by":"publisher","first-page":"943\u2013949","DOI":"10.1016\/S1470-2045(09)70232-3","article-title":"Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study","volume":"10","author":"Agnelli","year":"2009","journal-title":"Lancet Oncol"},{"key":"2025011107300095800_bib22","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to prevent venous thromboembolism in patients with cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"New Engl J Med"},{"key":"2025011107300095800_bib23","doi-asserted-by":"publisher","first-page":"618","DOI":"10.3390\/cancers12030618","article-title":"Primary thromboprophylaxis in pancreatic cancer patients: why clinical practice guidelines should be implemented","volume":"12","author":"Farge","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2025011107300095800_bib24","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.thromres.2023.05.017","article-title":"Arterial events in cancer patients treated with apixaban for venous thrombosis","volume":"228","author":"Larsen","year":"2023","journal-title":"Thromb Res"},{"key":"2025011107300095800_bib25","doi-asserted-by":"publisher","first-page":"e566","DOI":"10.1016\/S1470-2045(19)30336-5","article-title":"2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer","volume":"20","author":"Farge","year":"2019","journal-title":"Lancet Oncol"},{"key":"2025011107300095800_bib26","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1111\/jth.14564","article-title":"The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: guidance from the SSC of the ISTH","volume":"17","author":"Wang","year":"2019","journal-title":"J Thromb Haemost"},{"key":"2025011107300095800_bib27","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1159\/000444734","article-title":"Practice patterns for prophylaxis and treatment of venous thromboembolism in German cancer patients","volume":"39","author":"Matzdorff","year":"2016","journal-title":"Oncol Res Treat"},{"key":"2025011107300095800_bib28","doi-asserted-by":"publisher","first-page":"e868","DOI":"10.1200\/JOP.19.00697","article-title":"Successful model for guideline implementation to prevent cancer-associated thrombosis: venous thromboembolism prevention in the ambulatory Cancer clinic","volume":"16","author":"Holmes","year":"2020","journal-title":"JCO Oncol Pract"},{"key":"2025011107300095800_bib29","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1001\/jamasurg.2022.2590","article-title":"Evaluation of adherence to venous thromboembolism prophylaxis guidelines among US adults after pancreatic cancer surgery","volume":"157","author":"Perry","year":"2022","journal-title":"JAMA Surg"},{"key":"2025011107300095800_bib30","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1111\/jth.15175","article-title":"Discordant reporting of VTE in pancreatic cancer: a systematic review and meta-analysis of thromboprophylaxis versus chemotherapeutic trials","volume":"19","author":"Chiasakul","year":"2021","journal-title":"J Thromb Haemost"},{"key":"2025011107300095800_bib31","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1002\/sim.1023","article-title":"Individual patient- versus group-level data meta-regressions for the investigation of treatment effect modifiers: ecological bias rears its ugly head","volume":"21","author":"Berlin","year":"2002","journal-title":"Stat Med"},{"key":"2025011107300095800_bib32","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1161\/01.CIR.0000120509.64740.DC","article-title":"Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial","volume":"109","author":"Stellbrink","year":"2004","journal-title":"Circulation"},{"key":"2025011107300095800_bib33","doi-asserted-by":"publisher","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur Heart J"}],"container-title":["European Heart Journal - Cardiovascular Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ehjcvp\/advance-article-pdf\/doi\/10.1093\/ehjcvp\/pvae068\/60413225\/pvae068.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/10\/8\/665\/60413225\/pvae068.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article-pdf\/10\/8\/665\/60413225\/pvae068.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,11]],"date-time":"2025-01-11T07:30:09Z","timestamp":1736580609000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ehjcvp\/article\/10\/8\/665\/7756861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,13]]},"references-count":33,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,9,13]]},"published-print":{"date-parts":[[2025,1,11]]}},"URL":"https:\/\/doi.org\/10.1093\/ehjcvp\/pvae068","relation":{},"ISSN":["2055-6837","2055-6845"],"issn-type":[{"value":"2055-6837","type":"print"},{"value":"2055-6845","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,9,13]]}}}